Lupin launches Bromfenac Ophthalmic Solution, 0.075% in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of Bromfenac Ophthalmic Solution, 0.075%, after having received an approval from the United States Food and Drug Administration (U.S. FDA).

Bromfenac Ophthalmic Solution, 0.075% is a generic equivalent of BromSite® Ophthalmic Solution, 0.075%, of Sun Pharmaceutical Industries Limited. It is indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery.

Bromfenac Ophthalmic Solution 0.075% (RLD BromSite®) had estimated annual sales of USD 15 million in the U.S. (IQVIA MAT December 2023).

Shares of Lupin Limited was last trading in BSE at Rs. 1608.05 as compared to the previous close of Rs. 1595.70. The total number of shares traded during the day was 38522 in over 2568 trades.

The stock hit an intraday high of Rs. 1612.85 and intraday low of 1584.15. The net turnover during the day was Rs. 61525836.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 ProductLaunch BromfenacOphthalmicSolution